Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1026 clinical trials
Featured trial
A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Novel Anti-hormonal Therapy (NAH) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of NAH

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of NAH therapy. Meanwhile researchers want to compare the safety of …

  • 14 views
  • 08 Feb, 2022
  • 20 locations
Featured trial
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

Gene transfer is a new cancer therapy takes white blood cells from a person and grows them in a lab. The cells are changed with a virus to attack tumor cells, then returned to the person

metastatic cancer
renal cell cancer
primary cancer
carcinoma
clear cell carcinoma
  • 210 views
  • 22 Dec, 2020
  • 1 location
Featured trial
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.  

solid tumors
FGFR3
measurable disease
primary cancer
malignancy
  • 112 views
  • 10 May, 2022
  • 50 locations
Featured trial
PROSTATE CANCER RESEARCH STUDY

PROSTATE CANCER RESEARCH STUDY

  • 88 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer

A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer

  • 321 views
  • 25 Mar, 2021
  • 4 locations
Featured trial
Cancer: Do You Have Cancer and Problems With Constipation?

Cancer: Do You Have Cancer and Problems With Constipation?

  • 121 views
  • 08 Nov, 2020
  • 1 location
Featured trial
CALGB 80802: A Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).

CALGB 80802: A Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).

  • 84 views
  • 08 Nov, 2020
  • 1 location
Featured trial
Alliance A021202: Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors

Alliance A021202: Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors

  • 90 views
  • 08 Nov, 2020
  • 1 location
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of …

measurable disease
lung carcinoma
cancer chemotherapy
  • 3 views
  • 14 Sep, 2022
  • 78 locations
An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC) (daNIS-3)

The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti

  • 0 views
  • 15 Sep, 2022
  • 24 locations